Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
Precision oncology company Sentinal4D completes pre-seed funding round and launches to the public
Sentinal4D, a spinout company from The Institute of Cancer Research, London, has been announced to the public – having closed of its first round of funding and appointed its foundational leadership team.
Stars bring Christmas cheer to Carols from Chelsea
Christmas arrived in style as celebrities and guests got into the festive spirit at Carols from Chelsea – raising more than £125,000 for The Institute of Cancer Research, London
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer
One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
New understanding of aggressive form of breast cancer paves the way for tests and treatments
Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.